NCPL vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

NCPL

54.8
AI Score
VS
NCPL Wins

HIVE

53.7
AI Score

Investment Advisor Scores

NCPL

55score
Recommendation
HOLD

HIVE

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric NCPL HIVE Winner
Revenue 335,481 164.00M HIVE
Net Income -7.58M -221.61M NCPL
Gross Margin 96.7% -33.0% NCPL
Net Margin -2260.7% -135.1% HIVE
ROE -35.1% -60.8% NCPL
ROA -29.1% -25.8% HIVE
Total Assets 26.06M 857.69M HIVE
Current Ratio 0.26 1.55 HIVE

Relative Price Performance (Last 90 Days)

NCPL 1M: +10.1% · 3M: +451.9% HIVE 1M: -26.3% · 3M: -38.7%

Current Technical Phase

NCPL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (59.6% over 20 days), RSI 54

RSI (14): 53.9 · Price: $1.75

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.0%), weak momentum, RSI 33

RSI (14): 33.2 · Price: $1.65

Fundamentals Snapshot

Metric NCPL HIVE
Market Cap — —
Forward P/E 0.0 -3.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.4% 0.0%
Gross Margin 1.0% 0.3%
Operating Margin -13.0% -0.6%
EPS -15.17 -1.53
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, NCPL is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.